Patent · US Active

Inhibitors of bruton's tyrosine kinase

US8754091B2 · kind B2 · utility

59Cited by
22References
21Claims
0Family size

Assignee

Inventors

Key dates

Filing dateJul 5, 2012
Grant dateJun 17, 2014
Priority date
Expiry dateJul 5, 2032

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC07K2317/24
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

Disclosed herein are compounds, including compounds having the structure of Formula (A), (B), (C), and (D), as described in further detail herein, that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.